TARKINAID
Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases
| Coordinatore | SEMMELWEIS EGYETEM
Organization address
address: Ulloi ut 26 contact info |
| Nazionalità Coordinatore | Hungary [HU] |
| Totale costo | 3˙912˙000 € |
| EC contributo | 2˙999˙860 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SEMMELWEIS EGYETEM
Organization address
address: Ulloi ut 26 contact info |
HU (BUDAPEST) | coordinator | 551˙962.00 |
| 2 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 493˙280.00 |
| 3 |
UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
IT (VERONA) | participant | 296˙082.00 |
| 4 |
VICHEM CHEMIE KUTATO KFT
Organization address
address: HERMANN OTTO UTCA 15 contact info |
HU (BUDAPEST) | participant | 296˙010.00 |
| 5 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 295˙950.00 |
| 6 |
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
Organization address
address: AV BRIGADEIRO TROMPOWSKI SN 2 contact info |
BR (RIO DE JANEIRO) | participant | 246˙822.00 |
| 7 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 246˙228.00 |
| 8 |
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNASKAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
Organization address
address: ALEXANDER FLEMING STREET 34 contact info |
EL (VARI) | participant | 177˙570.00 |
| 9 |
AMBIOTIS SAS
Organization address
address: RUE JEANNE MARVIG 29 contact info |
FR (TOULOUSE) | participant | 147˙978.00 |
| 10 |
FUNDACAO OSWALDO CRUZ
Organization address
address: AVENIDA BRASIL 4365 contact info |
BR (RIO DE JANEIRO) | participant | 147˙978.00 |
| 11 |
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Organization address
address: VIA FIORENTINA 151 contact info |
IT (SIENA) | participant | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant consortium have recently obtained genetic evidence showing that myeloid Src-family kinases (Hck, Fgr and Lyn) are indispensable for murine models of autoimmune inflammatory diseases such as rheumatoid arthritis or blistering skin diseases. They also developed a number of novel Src-family kinase inhibitors that also block inflammation-related in vitro leukocyte functions. The applicants will test and further develop novel Src-family kinase inhibitors as anti-inflammatory compounds, using several in vitro and in vivo inflammation assays to optimize the structure of the selected molecules. They will also test whether Src-family inhibitors already in clinical use in oncology patients also inhibit inflammatory processes. Finally, they will use Src-family kinase-deficient mice in several inflammation models to test the role of those kinases in more detail and to provide further reference information for the consortium's preclinical drug development activity. The selected inhibitors and mutant mice will be pre-screened using various inflammation-related in vitro leukocyte functions and short-term in vivo inflammation models, and then analyzed in detail using a number of in vivo mouse models of chronic autoimmune and inflammatory diseases. The project is expected to result in development of novel preclinical drug candidates against chronic autoimmune and inflammatory disease with novel mechanism of action, as well as novel knowledge on the role of Src-family kinases in inflammatory diseases. The project will be performed in close cooperation between European and Brazilian scientists.'